TerrAscend (TSNDF) Income from Continuing Operations (2021 - 2026)
TerrAscend (TSNDF) reported Income from Continuing Operations of 6829000.0 for Q1 2026, up 10.91% year-over-year from 6157426.77 in Q1 2025, and down 554.12% quarter-over-quarter from 1044000.0 in Q4 2025.
TerrAscend (TSNDF) Income from Continuing Operations (2021 - 2026) Analysis & Trends
TerrAscend (TSNDF) has 6 years of Income from Continuing Operations data on file, last reported at 6829000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 6829000.0, up 10.91% year-over-year; the trailing twelve-month figure through Mar 2026 was 24186000.0 (down 24.93% YoY), and the FY2025 annual result was 25021000.0, down 19.77% from the prior year.
- Income from Continuing Operations declined to 6829000.0 in Q1 2026 per TSNDF's latest filing, from 1044000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 16859000.0 in Q2 2022 and troughed at 300561000.0 in Q3 2022.
- A 5-year average of 22672117.65 and a median of 7665000.0 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations plunged 638.3% in 2022, then jumped 758.72% in 2023.
- A 5-year view of Income from Continuing Operations shows it stood at 1950000.0 in 2022, then jumped by 758.72% to 12845000.0 in 2023, then fell by 18.83% to 10426000.0 in 2024, then plunged by 110.01% to 1044000.0 in 2025, then sank by 554.12% to 6829000.0 in 2026.
- Business Quant data shows TSNDF's Income from Continuing Operations at 6829000.0 in Q1 2026, 1044000.0 in Q4 2025, and 9907000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -92.12 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 118.42 Mn |
| 10 | TerrAscend | - | - | 34.60 Mn | -6.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.83 Mn |
| Dec 31, 2025 | -1.04 Mn |
| Sep 30, 2025 | -9.91 Mn |
| Jun 30, 2025 | -6.41 Mn |
| Mar 31, 2025 | -7.67 Mn |
| Dec 31, 2024 | 10.43 Mn |
| Sep 30, 2024 | -15.84 Mn |
| Jun 30, 2024 | -6.29 Mn |
| Mar 31, 2024 | -14.85 Mn |
| Dec 31, 2023 | 12.85 Mn |
| Sep 30, 2023 | -8.44 Mn |
| Jun 30, 2023 | -12.86 Mn |
| Mar 31, 2023 | -19.18 Mn |
| Dec 31, 2022 | -1.95 Mn |
| Sep 30, 2022 | -300.56 Mn |
| Jun 30, 2022 | 16.86 Mn |
| Mar 31, 2022 | -13.75 Mn |
| Dec 31, 2021 | 3.59 Mn |
| Sep 30, 2021 | 55.84 Mn |
| Jun 30, 2021 | -29.66 Mn |